This report describes and explains the advanced drug delivery systems market and covers 2018-2023, termed the historic period, and 2023-2028, 2033F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global advanced drug delivery systems market reached a value of nearly $259.24 billion in 2023, having grown at a compound annual growth rate (CAGR) of 6.2% since 2018. The market is expected to grow from $259.24 billion in 2023 to $373.4 billion in 2028 at a rate of 7.6%. The market is then expected to grow at a CAGR of 8.7% from 2028 and reach $566.44 billion in 2033.
Growth in the historic period resulted from the increased pharmaceutical research and development (R&D) expenditure, growing use of telemedicine services and rising healthcare expenditure. Factors that negatively affected growth in the historic period were product recalls.
Going forward, rising prevalence of chronic diseases, surging shift toward personalized medicine, increasing demand for early diagnosis of health problems and increasing growth in elderly population will drive the growth. Factor that could hinder the growth of the advanced drug delivery systems market in the future include risk of needlestick injuries.
The advanced drug delivery systems market is segmented by type into oral drug delivery system, injection-based drug delivery system, inhalation/pulmonary drug delivery system, transdermal drug delivery system, transmucosal drug delivery system, carrier-based drug delivery system and other types. The oral drug delivery system market was the largest segment of the advanced drug delivery systems market segmented by type, accounting for 39.9% or $103.46 billion of the total in 2023. Going forward, it is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by type, at a CAGR of 9% during 2023-2028.
The advanced drug delivery systems market is segmented by application into oncology, anti-infective, central nervous system, respiratory diseases, cardiovascular diseases, musculoskeletal disorders, metabolic disorders and other applications. The other applications market was the largest segment of the advanced drug delivery systems market segmented by application, accounting for 19.2% or $49.86 billion of the total in 2023. Going forward, the oncology segment is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by application, at a CAGR of 9.9% during 2023-2028.
The advanced drug delivery systems market is segmented by end user into hospitals, specialized clinics and other end users. The hospitals market was the largest segment of the advanced drug delivery systems market segmented by end user, accounting for 51.9% or $134.65 billion of the total in 2023. Going forward, the other end users segment is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by end user, at a CAGR of 7.9% during 2023-2028.
The advanced drug delivery systems market is segmented by carrier type into liposomes, nanoparticles, microspheres, monoclonal antibodies and other carrier types. The nanoparticles market was the largest segment of the advanced drug delivery systems market segmented by carrier type, accounting for 28% or $72.58 billion of the total in 2023. Going forward, it is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by carrier type, at a CAGR of 8.7% during 2023-2028.
The advanced drug delivery systems market is segmented by technology into prodrug, implants and intrauterine devices, targeted drug delivery, polymeric drug delivery and other technologies. The targeted drug delivery market was the largest segment of the advanced drug delivery systems market segmented by technology, accounting for 31.4% or $81.48 billion of the total in 2023. Going forward, it is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by technology, at a CAGR of 8.7% during 2023-2028.
North America was the largest region in the advanced drug delivery systems market, accounting for 40% or $103.62 billion of the total in 2023. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the advanced drug delivery systems market will be Asia Pacific and Western Europe where growth will be at CAGRs of 8% and 7.8% respectively. These will be followed by North America and Eastern Europe where the markets are expected to grow at CAGRs of 7.6% and 6.5% respectively.
The global advanced drug delivery systems market is highly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up to 2.91% of the total market in 2022. The market concentration can be attributed to the presence of large number of players in different geographies. Prominent players are acquiring the products and entering into partnerships with the other companies to consolidate their market positions across the globe, while others are distributing products. Johnson & Johnson, Inc was the largest competitor with a 0.50% share of the market, followed by Baxter with 0.48%, Becton, Dickinson and Company with 0.46%, Medtronic Plc with 0.31%, Pacira BioSciences, Inc. with 0.26%, Abbvie, Inc. with 0.24%, Gilead Sciences, Inc. with 0.20%, Merck KGaA with 0.17%, Danaher Corporation with 0.14% and Bausch Health Companies Inc with 0.14%.
The top opportunities in the advanced drug delivery systems market segmented by type will arise in the oral drug delivery system segment, which will gain $56.07 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by application will arise in the oncology segment, which will gain $28.36 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by end user will arise in the hospitals segment, which will gain $58.53 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by carrier type will arise in the nanoparticles segment, which will gain $37.65 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by technology will arise in the targeted drug delivery segment, which will gain $42.22 billion of global annual sales by 2028. The advanced drug delivery systems market size will gain the most in the USA at $37.87 billion.
Market-trend-based strategies for the advanced drug delivery systems market include introducing preclinical drug development with advanced drug delivery technology, increasing focus dissolving microneedle drug delivery methods, innovative on-body delivery systems for subcutaneous therapies, pioneering advanced drug delivery with thin film formulation and strategic partnerships and collaborations among market players to drive innovation and expansion in the market.
Player-adopted strategies in the advanced drug delivery systems market include expanding operations by new drug developments/approvals, expanding operations through acquisitions, expanding operations through innovations and expanding operations through strategic acquisitions.
To take advantage of the opportunities, the analyst recommends the advanced drug delivery systems companies to focus on advancing preclinical drug development with innovative technology, focus on dissolving microneedle drug delivery methods, focus on on-body delivery systems for subcutaneous therapies, focus on technological advancements in drug delivery, focus on oral and inhalation drug delivery systems, focus on targeted drug delivery and polymeric drug delivery, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for brain-targeted drug delivery, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, focus on tailored solutions for end-users and focus on hospitals segment.
The global advanced drug delivery systems market reached a value of nearly $259.24 billion in 2023, having grown at a compound annual growth rate (CAGR) of 6.2% since 2018. The market is expected to grow from $259.24 billion in 2023 to $373.4 billion in 2028 at a rate of 7.6%. The market is then expected to grow at a CAGR of 8.7% from 2028 and reach $566.44 billion in 2033.
Growth in the historic period resulted from the increased pharmaceutical research and development (R&D) expenditure, growing use of telemedicine services and rising healthcare expenditure. Factors that negatively affected growth in the historic period were product recalls.
Going forward, rising prevalence of chronic diseases, surging shift toward personalized medicine, increasing demand for early diagnosis of health problems and increasing growth in elderly population will drive the growth. Factor that could hinder the growth of the advanced drug delivery systems market in the future include risk of needlestick injuries.
The advanced drug delivery systems market is segmented by type into oral drug delivery system, injection-based drug delivery system, inhalation/pulmonary drug delivery system, transdermal drug delivery system, transmucosal drug delivery system, carrier-based drug delivery system and other types. The oral drug delivery system market was the largest segment of the advanced drug delivery systems market segmented by type, accounting for 39.9% or $103.46 billion of the total in 2023. Going forward, it is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by type, at a CAGR of 9% during 2023-2028.
The advanced drug delivery systems market is segmented by application into oncology, anti-infective, central nervous system, respiratory diseases, cardiovascular diseases, musculoskeletal disorders, metabolic disorders and other applications. The other applications market was the largest segment of the advanced drug delivery systems market segmented by application, accounting for 19.2% or $49.86 billion of the total in 2023. Going forward, the oncology segment is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by application, at a CAGR of 9.9% during 2023-2028.
The advanced drug delivery systems market is segmented by end user into hospitals, specialized clinics and other end users. The hospitals market was the largest segment of the advanced drug delivery systems market segmented by end user, accounting for 51.9% or $134.65 billion of the total in 2023. Going forward, the other end users segment is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by end user, at a CAGR of 7.9% during 2023-2028.
The advanced drug delivery systems market is segmented by carrier type into liposomes, nanoparticles, microspheres, monoclonal antibodies and other carrier types. The nanoparticles market was the largest segment of the advanced drug delivery systems market segmented by carrier type, accounting for 28% or $72.58 billion of the total in 2023. Going forward, it is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by carrier type, at a CAGR of 8.7% during 2023-2028.
The advanced drug delivery systems market is segmented by technology into prodrug, implants and intrauterine devices, targeted drug delivery, polymeric drug delivery and other technologies. The targeted drug delivery market was the largest segment of the advanced drug delivery systems market segmented by technology, accounting for 31.4% or $81.48 billion of the total in 2023. Going forward, it is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by technology, at a CAGR of 8.7% during 2023-2028.
North America was the largest region in the advanced drug delivery systems market, accounting for 40% or $103.62 billion of the total in 2023. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the advanced drug delivery systems market will be Asia Pacific and Western Europe where growth will be at CAGRs of 8% and 7.8% respectively. These will be followed by North America and Eastern Europe where the markets are expected to grow at CAGRs of 7.6% and 6.5% respectively.
The global advanced drug delivery systems market is highly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up to 2.91% of the total market in 2022. The market concentration can be attributed to the presence of large number of players in different geographies. Prominent players are acquiring the products and entering into partnerships with the other companies to consolidate their market positions across the globe, while others are distributing products. Johnson & Johnson, Inc was the largest competitor with a 0.50% share of the market, followed by Baxter with 0.48%, Becton, Dickinson and Company with 0.46%, Medtronic Plc with 0.31%, Pacira BioSciences, Inc. with 0.26%, Abbvie, Inc. with 0.24%, Gilead Sciences, Inc. with 0.20%, Merck KGaA with 0.17%, Danaher Corporation with 0.14% and Bausch Health Companies Inc with 0.14%.
The top opportunities in the advanced drug delivery systems market segmented by type will arise in the oral drug delivery system segment, which will gain $56.07 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by application will arise in the oncology segment, which will gain $28.36 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by end user will arise in the hospitals segment, which will gain $58.53 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by carrier type will arise in the nanoparticles segment, which will gain $37.65 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by technology will arise in the targeted drug delivery segment, which will gain $42.22 billion of global annual sales by 2028. The advanced drug delivery systems market size will gain the most in the USA at $37.87 billion.
Market-trend-based strategies for the advanced drug delivery systems market include introducing preclinical drug development with advanced drug delivery technology, increasing focus dissolving microneedle drug delivery methods, innovative on-body delivery systems for subcutaneous therapies, pioneering advanced drug delivery with thin film formulation and strategic partnerships and collaborations among market players to drive innovation and expansion in the market.
Player-adopted strategies in the advanced drug delivery systems market include expanding operations by new drug developments/approvals, expanding operations through acquisitions, expanding operations through innovations and expanding operations through strategic acquisitions.
To take advantage of the opportunities, the analyst recommends the advanced drug delivery systems companies to focus on advancing preclinical drug development with innovative technology, focus on dissolving microneedle drug delivery methods, focus on on-body delivery systems for subcutaneous therapies, focus on technological advancements in drug delivery, focus on oral and inhalation drug delivery systems, focus on targeted drug delivery and polymeric drug delivery, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for brain-targeted drug delivery, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, focus on tailored solutions for end-users and focus on hospitals segment.
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Advanced Drug Delivery Systems Market - Macro Economic Scenario
9 Global Market Size and Growth
10 Global Advanced Drug Delivery Systems Market Segmentation
11 Advanced Drug Delivery Systems Market, Regional and Country Analysis
12 Asia-Pacific Market
13 Western Europe Market
14 Eastern Europe Market
15 North America Market
16 South America Market
17 Middle East Market
18 Africa Market
19 Competitive Landscape and Company Profiles
20 Advanced Drug Delivery Systems Market Other Major and Innovative Companies
23 Key Mergers and Acquisitions
24 Opportunities and Strategies
25 Advanced Drug Delivery Systems Market, Conclusions and Recommendations
26 Appendix
Executive Summary
Advanced Drug Delivery Systems Global Market Opportunities And Strategies To 2033 provides the strategists; marketers and senior management with the critical information they need to assess the global advanced drug delivery systems market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies based on local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for advanced drug delivery systems? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The advanced drug delivery systems market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider advanced drug delivery systems market; and compares it with other markets.
The report covers the following chapters:
- Introduction And Market Characteristics: Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by carrier type, by technology, by application and by end user.
- Key Trends: Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario: The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the advanced drug delivery systems market.
- Global Market Size And Growth: Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis: Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
- Market Segmentation: Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by type, by carrier type, by technology, by application and by end user in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
- Regional Market Size And Growth - Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape: Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies: Details on the company profiles of other major and innovative companies.
- Competitive Benchmarking: Briefs on the financials comparison between major players in the market
- Competitive Dashboard: Briefs on competitive dashboard of major players.
- Key Mergers And Acquisitions: Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations - This section includes recommendations for advanced drug delivery systems providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Scope
Markets Covered:
1) By Type: Oral Drug Delivery System; Injection-Based Drug Delivery System; Inhalation/Pulmonary Drug Delivery System; Transdermal Drug Delivery System; Transmucosal Drug Delivery System; Carrier-Based Drug Delivery System And Other Types.2) By Carrier Type: Liposomes; Nanoparticles; Microspheres; Monoclonal Antibodies; Other Carrier Types.
3) By Technology: Prodrug; Implants And Intrauterine Devices; Targeted Drug Delivery; Polymeric Drug Delivery; Other Technologies.
4) By Application: Oncology; Anti-Infective; Central Nervous System; Respiratory Diseases; Cardiovascular Diseases; Musculoskeletal Disorders; Metabolic Disorders; Other Applications.
5) By End User: Hospitals; Specialized Clinics; Other End Users
Key Companies Mentioned: Johnson & Johnson, Inc; Baxter; Becton, Dickinson And Company; Medtronic Plc; Pacira Biosciences, Inc
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; advanced drug delivery systems indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- Johnson & Johnson, Inc
- Baxter
- Becton, Dickinson and Company
- Medtronic Plc
- Pacira BioSciences, Inc
- Abbvie, Inc
- Gilead Sciences Inc
- Merck KGaA
- Danaher Corporation
- Bausch Health Companies Inc
- Sun Pharma Advanced Research Company (SPARC)
- Gufic Biosciences Ltd
- Lonza
- Fosun Pharma (Fosun International)
- Luye pharma
- Acino Pharma AG
- MedAlliance SA
- AstraZeneca
- Mundipharma
- Evonik Industries AG
- SHL Medical AG
- Bayer AG
- Bristol Myers Squibb
- Amgen Inc
- Gilead Sciences, Inc
- Eli Lilly and Company
- Biogen Inc
- Ache Laboratorios Farmaceuticos
- Eurofarma Laboratorios EMS S.A
- Cristalia Produtos Quimicos Farmaceuticos Ltd
- Libbs Farmaceutica Ltd
- Laboratorios Richmond S.A.C.I.F
- Gador S.A
- Roemmers S.A.C.I.F.A
- Laboratorio Elea Phoenix andromaco S.A
- Biosano Laboratorios
- Laboratorios Recalcine
- Laboratorios Procaps
- Laboratorios Vita
- Laboratorios Lafrancol
- Laboratorios Quifar
- Laboratorio Franco Colombiano LAFRANCOL
- Laboratorios Bago del Peru
- Laboratorios Pharmabiotics
- Laboratorios Raffo
- Eitan Medical Limited
- Sorrel Medical
- Boehringer Ingelheim United Arab Emirates
- SHL Medical
- Fertin Pharma A/S
- Boston Scientific Corporation
- Kindeva Drug Delivery L.P
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 358 |
Published | April 2024 |
Forecast Period | 2023 - 2033 |
Estimated Market Value ( USD | $ 259.2 Billion |
Forecasted Market Value ( USD | $ 566.4 Billion |
Compound Annual Growth Rate | 8.1% |
Regions Covered | Global |
No. of Companies Mentioned | 52 |